Aerovate Therapeutics Inc (AVTE) - Total Assets
Based on the latest financial reports, Aerovate Therapeutics Inc (AVTE) holds total assets worth $77.53 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See debt-free asset ratio of Aerovate Therapeutics Inc to measure how much of total assets are equity-financed.
Aerovate Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Aerovate Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check AVTE goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Aerovate Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Aerovate Therapeutics Inc's total assets of $77.53 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Aerovate Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Aerovate Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aerovate Therapeutics Inc's current assets represent 99.7% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 42.0% of total assets in 2024, down from 100.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aerovate Therapeutics Inc Competitors by Total Assets
Key competitors of Aerovate Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Aerovate Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 32.01 | 6.65 | 2.64 |
| Quick Ratio | 32.01 | 6.65 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $74.96 Million | $87.72 Million | $2.90 Million |
Aerovate Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Aerovate Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 35.57 |
| Latest Market Cap to Assets Ratio | 0.97 |
| Asset Growth Rate (YoY) | -37.0% |
| Total Assets | $80.33 Million |
| Market Capitalization | $77.68 Million USD |
Valuation Analysis
Near Book Valuation: The market values Aerovate Therapeutics Inc's assets close to their book value (0.97x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Aerovate Therapeutics Inc's assets decreased by 37.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aerovate Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Aerovate Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $80.33 Million | -36.95% |
| 2023-12-31 | $127.42 Million | -5.83% |
| 2022-12-31 | $135.30 Million | -22.85% |
| 2021-12-31 | $175.36 Million | +3619.26% |
| 2020-12-31 | $4.71 Million | +34.18% |
| 2019-12-31 | $3.51 Million | -- |
About Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.